August 17, 2015 – The National Eczema Association (NEA) is pleased to share news about a potential new topical non-steroidal treatment for mild-to-moderate eczema that you, the National Eczema Association community, helped make possible.
July 20, 2015 – Researchers at Yale School of Medicine have successfully treated patients with moderate to severe eczema using a rheumatoid arthritis drug.
July 13, 2015 – Anacor Pharmaceuticals Announces Positive Top-Line Results From Two Phase 3 Pivotal Studies of Crisaborole Topical Ointment, 2% in Patients With Mild-to-Moderate Atopic Dermatitis.
July 10, 0215 – Eczema can be challenging any time of year. Here are some tips for managing eczema during the summer from people just like you, friends on NEA’s Facebook page.
May 7, 2015 – Researchers from St. Jude Children’s Research Hospital have identified a protein that offers a new focus for developing targeted therapies to tame severe inflammation. Targeting this protein has lead to a greater understanding on how mutations in a protein can lead to atopic dermatitis.
May 7, 2015 – Inflammation, once merely considered the body’s healing response, is now the subject of close scrutiny as a key component of many diseases. Arthritis and inflammation have been linked for decades, but the inflammatory response is also taking center stage in heart disease, cancer, diabetes, asthma, and Alzheimer’s disease.
NEA formed a Scientific Advisory Committee Task Force to conduct a systematic review of topical corticosteroid withdrawal/topical steroid addiction in patients with atopic dermatitis and other dermatoses, and created a NEA education announcement on Topical Steroid Addiction/Withdrawal.
March 10, 2015 – There seem to be three major reasons why patients seek alternative medicine for atopic dermatitis: First, we simply don’t yet have a cure for this disease. Second, we can’t yet clearly explain why this disease occurs. While doctors try hard to describe factors that play a role in atopic dermatitis, such as cytokines and inflammatory cells, we still can’t pinpoint the root of the disease. Third, the outcomes of conventional atopic dermatitis treatments are not always consistent, and sometimes they are perceived as being unsafe.
March 10, 2015 – On March 9, 2015, NEA CEO Julie Block, 13-year old eczema patient Isaiah, 17-year old eczema patient Gracie, and their parents were present at an important Food and Drug Administrative (FDA) hearing regarding the unmet medical need for atopic dermatitis therapies in pediatrics.
March 5, 2015 – Check out this NPR piece on an important new study about how eczema affects the lives of people who have it by NEA Scientific Advisory Committee member Jonathan Silverberg, MD. Data from this study demonstrates the burden of living with eczema, which helps further the case for more eczema research.